FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 0 4 2005

ATTY. DOCKET NO. HA726 DIV APPLICATION NO. 10/660,878 APPLICANT ATWAL ET AL. FILING DATE

SEPTEMBER 12, 2003

Group 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
A	\					
AE	3		•			
A						
Al						
A						
Al						
A	3					
Al	1					
Al						·
A	J					
Al	(,			
Al						
		FOREIGN	PATENT DOCUMENTS			

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN: YES	SLATION NO
V)R	AM	GB 1596320	8/26/81	London (English equivalent of HU 182460)				
	AN							
	AO	,						
	AP							
	AQ							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)								

		,		· • · · · · · · · · · · · · · · · · · ·
	AR			
	AS	. •	·	•
	AT			
EXAMIN	ER	Unrak Rego	DATE CONSIDERED	4/18/05

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

040.36.2004 - 4:40 BATENING PATENT DEP FIRE INFORMATION DISCLOSURE CHAILUN

(Use several sheets if necessary)

S.N. 10/2 27/278 Afty Docket No. HA 726 DIV
Group 1624

			U.S.	PATENT DOCUMENTS					
EXAMPLER DATEAL		DOCUMENT NUMBER	DATE	NAME	С	€2A	SUBCLA	5 9	FILING DATE
	AA	J							
	AB								
	AC								
	AD								
	AE								
	AF			·					
	AG								
	AH								
*	AJ								
	AJ								
	AK								
	AL								
			FOREIG	N PATENT DOCUMENTS					
·		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUB	CLASS	TRA YES	NSLATION NO
	AM	_							
	AN								
	AO								
	AP								
	AQ	. •	٠,				,		
		• •	·	Including Author, Title, Date, Perline					
	AR	Cochran et al., "Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K+-channels," Eur J Neurosci: 2001 Nov;14(9):1455-63;							
MOR	AS	Coleman et al., "Subur Aug;73(2):849-58;	nit composit	lon of Kv1 channels in human (n l",eac	euroc	hem. 19	99	

"EXAMINER: tritial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Davies et al., "Kv channel subunit expression in rat pulmonary arteries," Lung. 2001;179(3):147-61. Epub 2002 Feb 04;

4/18/05

HARDHARI DIN DISCLOSURE CHATTON

(Use several sheets if necessary)

S.N. 10.29.23,8, 56


PHy. Docket No. HA726DIV

Group 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

10R	AA	Frey et al., "Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine," Neurogastroenterol Motil. 2000 Dec;12(6):509-16;				
10R	AB	Hanson et al., "UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage- gated potassium channel and inhibits human T cell activation," British Journal of Pharmacology (1999), 128, 1707-1716;				
NOR	AC	Hatton et al., "Functional and molecular expression of a voltage-dependent K(+) charmel (Kv1.1) in interstitial cells of Cajal," J Physiol. 2001 Jun 1;533 (Pt 2):315-27;				
WR	ΑĎ	Koh et al., "Contribution of dalayed rectifier potassium currents to the electrical activity of murine colonic smooth muscle," J Physiol. 1999 Mar 1; 515 (Pt 2):475-87.				
WK.	AE	Kourrich et al., "Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats," Behav Brain Res. 2001 Apr 8;120(1):35-46.				
NOR.	AF	Lopantsev et al., "Hyperexcitability of CA3 pyramidal cells in mice lacking the potassium channel subunit Kv1.1," Epilepsia. 2003 Dec;44(12):1506-12;				
18R	AG	MacDonald et al., "Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion," Mol Endocrinol. 2001 Aug; 15(8):1423-35;				
NEK	AH	MacDonald et al., "Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets," Diabetologia. 2003 Aug;46(8):1048-62. Epub 2003 Jun 27.				
∞0K	AJ	Pozeg et al., "In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rate," Circulation. 2003 Apr 22;107(15):2037-44. Epub 2003 Apr 14.				
086	A.J	Rho et al., "Developmental seizure susceptibility of kv1.1 potassium channel knockout mice," Dev Neurosci. 1999 Nov;21(3-5):320-7;				
00K	AK	Shah et al., "Immunosuppressive effects of a Kv1.3 inhibitor," Cellular Immunology 221, (2003), 100-106.				
NOR.	AL	Vianna-Jorge et al., "Shaker-type Kv1 channel blockers increase the peristaltic activity of guinea- pig ileum by stimulating acetylcholine and tachykinins release by the enterio nervous system," Br J Pharmacol. 2003 Jan; 138(1):57-62;				
VER	AM	Wickenden, "Potassium channels as anti-epileptio drug targets," Neuropharmacology. 2002 Dec;43(7):1055-80.				
NSX	AN	Wulff et al., "Potassium channels as therapeutic targets for autoimmune disorders," Current Opinion in Drug Discovery & Development 2003 6(5):640-647.				
EXAMINE	₹	Burk Cers DATE CONSIDERED 4/18/05				

"EXAMINER: Initial of reference considered, whether or not cliation is in conformance with MPEP 609: Draw a line through cliation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



(Use several shoets if necessary)

5/12: 10/60.6578

AHY DOCKET NO. HATTEDIN

Group /624

OTHER DOCUMENTS (Including Author, Tide, Date, Portinent pages, Etc.)

1DR	AA	Xu et al., The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensit Natl Acad Sci U S A. 2004 Mar 2;101(9):3112-7. Epub 2004 Feb 23 (epublished 2004 Fe						
	AB			,				
	AC	·						
	AD		· · · · · · · · · · · · · · · · · · ·					
.,	AE							
	AF.		•					
	AG							
·	АН	·						
	AI		· · · · · · · · · · · · · · · · · · ·					
	AJ	·						
·	AK				—			
	AL		-					
	AM	•			_			
	AN							
EXAMINE	1	Duyak Raf DA	E CONSIDERED	4/18/05	<u> </u>			

*EXAMINER: Initial of reference considered, whether or not challon is in conformance with MPEP 809: Draw a line through challon if not in conformance and not considered. Include a copy of this form with the next communication to applicant.